Lu-PSMA (Sartor et al., 2021) (Lutetium-177 labeled prostate-specific membrane antigen ligand) is a radionuclide therapy that achieves precise targeting of tumors by targeting PSMA receptors over-expressed on the surface of PCa cells. The gene discussed is FOLH1; the disease is posterior cortical atrophy.